The functional G143E variant of carboxylesterase 1 is associated with increased clopidogrel active metabolite levels and greater clopidogrel response

Pharmacogenetics and Genomics

Volumn 23, Issue 1, 2013, Pages 1-8

  Lewis, Joshua P ^a   Horenstein, Richard B ^a   Ryan, Kathleen ^a   O'Connell, Jeffrey R ^a   Gibson, Quince ^a   Mitchell, Braxton D ^a   Tanner, Keith ^a   Chai, Sumbul ^a   Bliden, Kevin P ^b   Tantry, Udaya S ^b   Peer, Cody J ^d   Figg, William D ^d   Spencer, Shawn D ^e   Pacanowski, Michael A ^f   Gurbel, Paul A ^b   Shuldiner, Alan R ^a,c  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b SINAI CENTER FOR THROMBOSIS RESEARCH   (United States)

^c BALTIMORE VA MEDICAL CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

^e SAIC FREDERICK INC   (United States)

^f CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

carboxylesterase 1; CES1; clopidogrel; percutaneous coronary intervention; pharmacogenetics

Indexed keywords

CARBOXYLESTERASE; CARBOXYLESTERASE 1; CLOPIDOGREL; UNCLASSIFIED DRUG;

ADULT; ALLELE; ANTICOAGULANT THERAPY; ARTICLE; CARDIOVASCULAR EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG TRANSFORMATION; GENOTYPE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; PHARMACOGENOMICS; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION;

EID: 84871919080     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32835aa8a2     Document Type: Article

References (32)

1. Dansette PM, Rosi J, Bertho G, Mansuy D. Cytochromes P450 catalyze bothsteps of the major pathway of clopidogrel bioactivation, whereasparaoxonase catalyzes the formation of a minor thiol metabolite isomer.Chem Res Toxicol 2012; 25:348-356.
2. Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronarystenting: response variability, drug resistance, and the effect of pretreatmentplatelet reactivity. Circulation 2003; 107:2908-2913. (Pubitemid 36736631)
3. Shuldiner AR, O'Connell JR, Bliden KP, Gandhi A, Ryan K, Horenstein RB,et al. Association of cytochrome P450 2C19 genotype with the antiplateleteffect and clinical efficacy of clopidogrel therapy. JAMA 2009; 302:849-857.
4. Mega JL, Simon T, Collet JP, Anderson JL, Antman EM, Bliden K, et al.Reduced-function CYP2C19 genotype and risk of adverse clinicaloutcomes among patients treated with clopidogrel predominantly for PCI:a meta-analysis. JAMA 2010; 304:1821-1830.
5. Xie HG, Zou JJ, Hu ZY, Zhang JJ, Ye F, Chen SL. Individual variability in thedisposition of and response to clopidogrel: pharmacogenomics and beyond.Pharmacol Ther 2011; 129:267-289.
6. Zhu HJ, Patrick KS, Yuan HJ, Wang JS, Donovan JL, DeVane CL, et al.Two CES1 gene mutations lead to dysfunctional carboxylesterase 1 activityin man: clinical significance and molecular basis. Am J Hum Genet 2008;82:1241-1248.
7. Shi D, Yang J, Yang D, LeCluyse EL, Black C, You L, et al. Anti-influenzaprodrug oseltamivir is activated by carboxylesterase human carboxylesterase1, and the activation is inhibited by antiplatelet agent clopidogrel.J Pharmacol Exp Ther 2006; 319:1477-1484.
8. Vistoli G, Pedretti A, Mazzolari A, Bolchi C, Testa B. Influence of ionizationstate on the activation of temocapril by hCES1: a molecular- dynamicsstudy. Chem Biodivers 2009; 6:2092-2100.
9. Zhu HJ, Appel DI, Johnson JA, Chavin KD, Markowitz JS. Roleof carboxylesterase 1 and impact of natural genetic variants on the hydrolysisof trandolapril. Biochem Pharmacol 2009; 77:1266-1272.
10. Tabata T, Katoh M, Tokudome S, Nakajima M, Yokoi T. Identificationof the cytosolic carboxylesterase catalyzing the 50-deoxy-5-fluorocytidineformation from capecitabine in human liver. Drug Metab Dispos 2004;32:1103-1110. (Pubitemid 39287584)
11. Bouman HJ, Schomig E, van Werkum JW, Velder J, Hackeng CM,Hirschhauser C, et al. Paraoxonase-1 is a major determinant of clopidogrelefficacy. Nat Med 2011; 17:110-116.
12. Savi P, Pereillo JM, Uzabiaga MF, Combalbert J, Picard C, Maffrand JP, et al.Identification and biological activity of the active metabolite of clopidogrel.Thromb Haemost 2000; 84:891-896.
13. Scott SA, Sangkuhl K, Gardner EE, Stein CM, Hulot JS, Johnson JA, et al.Clinical pharmacogenetics implementation consortium guidelines forcytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.Clin Pharmacol Ther 2011; 90:328-332.
14. Lewis JP, Fisch AS, Ryan K, O'Connell JR, Gibson Q, Mitchell BD, et al.Paraoxonase 1 (PON1) gene variants are not associated with clopidogrelresponse. Clin Pharmacol Ther 2011; 90:568-574.
15. Antman EM, Hand M, Armstrong PW, Bates ER, Green LA, Halasyamani LK,et al. 2007 Focused update of the ACC/AHA 2004 guidelines for themanagement of patients with ST-elevation myocardial infarction: a report ofthe American College of Cardiology/American Heart Association Task Forceon practice guidelines: developed in collaboration with the CanadianCardiovascular Society endorsed by the American Academy of FamilyPhysicians: 2007 Writing Group to review new evidence and updatethe ACC/AHA 2004 guidelines for the management of patients withST-elevation myocardial infarction, writing on behalf of the 2004 WritingCommittee. Circulation 2008; 117:296-329.
16. Applegate SL, Rice MS, Stein F, Maitra KK. Knowledge of results andlearning to tell the time in an adult male with an intellectual disability:a single-subject research design. Occup Ther Int 2008; 15:32-44.
17. Peer CJ, Spencer SD, Vandenberg DA, Pacanowski MA, Horenstein RB,Figg WD. A sensitive and rapid ultra HPLC-MS/MS method for thesimultaneous detection of clopidogrel and its derivatized active thiolmetabolite in human plasma. J Chromatogr B Analyt Technol Biomed LifeSci 2012; 880:132-139.
18. Agarwala R, Biesecker LG, Hopkins KA, Francomano CA, Schaffer AA.Software for constructing and verifying pedigrees within large genealogiesand an application to the Old Order Amish of Lancaster County. GenomeRes 1998; 8:211-221. (Pubitemid 28177233)
19. Mega JL, Close SL,Wiviott SD, Shen L,Walker JR, Simon T, et al. Geneticvariants in ABCB1 and CYP2C19 and cardiovascular outcomes aftertreatment with clopidogrel and prasugrel in the TRITON-TIMI 38 trial:a pharmacogenetic analysis. Lancet 2010; 376:1312-1319.
20. Bouman HJ, van Werkum JW, Rudez G, Leebeek FW, Kruit A, Hackeng CM,et al. The influence of variation in the P2Y12 receptor gene on in vitroplatelet inhibition with the direct P2Y12 antagonist cangrelor. ThrombHaemost 2010; 103:379-386.
21. Li Y, Tang HL, Hu YF, Xie HG. The gain-of-function variant alleleCYP2C19 17: a double-edged sword between thrombosis and bleedingin clopidogrel-treated patients. J Thromb Haemost 2012; 10:199-206.
22. Jeong YH, Tantry US, Kim IS, Koh JS, Kwon TJ, Park Y, et al. Effect ofCYP2C19 2 and 3 loss-of-function alleles on platelet reactivity andadverse clinical events in East Asian acute myocardial infarction survivorstreated with clopidogrel and aspirin. Circ Cardiovasc Interv 2011; 4:585-594.
23. Di Castelnuovo A, de Gaetano G, Benedetta Donati M, Iacoviello L. Plateletglycoprotein IIb/IIIa polymorphism and coronary artery disease: implicationsfor clinical practice. Am J Pharmacogenomics 2005; 5:93-99. (Pubitemid 40593435)
24. Lev EI, Patel RT, Guthikonda S, Lopez D, Bray PF, Kleiman NS. Geneticpolymorphisms of the platelet receptors P2Y(12), P2Y(1) and GP IIIaand response to aspirin and clopidogrel. Thromb Res 2007; 119:355-360. (Pubitemid 44918095)
25. Cayla G, Hulot JS, O'Connor SA, Pathak A, Scott SA, Gruel Y, et al. Clinical,angiographic, and genetic factors associated with early coronary stentthrombosis. JAMA 2011; 306:1765-1774.
26. Satoh T, Hosokawa M. Structure, function and regulationof carboxylesterases. Chem Biol Interact 2006; 162:195-211.
27. Yang J, Shi D, Yang D, Song X, Yan B. Interleukin-6 alters the cellularresponsiveness to clopidogrel, irinotecan, and oseltamivir by suppressingthe expression of carboxylesterases HCE1 and HCE2. Mol Pharmacol2007; 72:686-694. (Pubitemid 47347303)
28. Fleming CD, Bencharit S, Edwards CC, Hyatt JL, Tsurkan L, Bai F, et al.Structural insights into drug processing by human carboxylesterase 1:tamoxifen, mevastatin, and inhibition by benzil. J Mol Biol 2005; 352:165-177. (Pubitemid 41207447)
29. Legler PM, Kumaran D, Swaminathan S, Studier FW, Millard CB. Structuralcharacterization and reversal of the natural organophosphate resistance ofa D-type esterase, Saccharomyces cerevisiae S- formylglutathionehydrolase. Biochemistry 2008; 47:9592-9601.
30. Mandrich L, Menchise V, Alterio V, De Simone G, Pedone C, Rossi M, et al.Functional and structural features of the oxyanion hole in a thermophilicesterase from Alicyclobacillus acidocaldarius. Proteins 2008; 71:1721-1731. (Pubitemid 351732930)
31. Wu D, Li Y, Song G, Zhang D, Shaw N, Liu ZJ. Crystal structure of humanesterase D: a potential genetic marker of retinoblastoma. FASEB J 2009;23:1441-1446.
32. Farid NA, Kurihara A, Wrighton SA. Metabolism and disposition of thethienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrelin humans. J Clin Pharmacol 2010; 50:126-142.